Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 458-469

  Navarro, Geraldine ^a   Taroumian, Sara ^a   Barroso, Nashla ^a   Duan, Lewei ^a   Furst, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse events; Efficacy; Expert opinion; Meta analysis; Rheumatoid arthritis; Side effects; Tocilizumab; Toxicity

Indexed keywords

ADVERSE EVENTS; EFFICACY; EXPERT OPINION; META-ANALYSIS; RHEUMATOID ARTHRITIS; SIDE EFFECTS; TOCILIZUMAB; TOXICITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; TREATMENT OUTCOME;

EID: 84894901070     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.08.001     Document Type: Article

References (43)

1. Guidelines. ACoRSoRA. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002, 46:328-346. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
2. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
3. Higashida J., Wun T., Schmidt S., Naguwa S.M., Tuscano J.M. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005, 32:2109-2115.
4. Young A., Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:907-927.
5. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010, 87:483-487.
6. Brandão F.M., Coelho P., Pinto P., Combe B. Tocilizumab-a new step in rheumatoid arthritis treatment. Acta Reumatol Port 2010, 35:302-312.
7. Alves J.D., Marinho A., Serra M.J. Tocilizumab: is there life beyond anti-TNF blockade?. Int J Clin Pract 2011, 65:508-513.
8. Kaly L., Rosner I. Tocilizumab-a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012, 26:157-165.
9. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011, 13:S5.
10. Smolen J.S., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011, 63:43-52.
11. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007, 30:2001-2006.
12. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
13. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
14. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12-19.
15. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
16. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
17. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523.
18. Kremer J.M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.
19. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980.
20. Yazici Y., Curtis J.R., Ince A., Baraf H., Malamet R.L., Teng L.L., et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012, 71:198-205.
21. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Bröll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-2829.
22. Dougados M., Kissel K., Sheeran T., Tak P.P., Conaghan P.G., Mola E.M., et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013, 72:43-50.
23. Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013, 381(9877):1541-1550.
24. Schiff M.H., Kremer J.M., Jahreis A., Vernon E., Isaacs J.D., van Vollenhoven R.F. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13:R141.
25. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
26. van Vollenhoven R.F., Geborek P., Forslind K., Albertsson K., Ernestam S., Petersson I.F., et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012, 379:1712-1720.
27. US food and drug administration. Code of federal regulations. Title 21. [cited 2012 July 30]. Volume 5. Available from. http://www.accessdata.fda.gov.
28. Zimmerman H. Drug-induced liver disease. Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver 1978, Appleton-Century-Crofts, New York, (p. 351-3).
29. Genovese M.C., Smolen J.S., Emery P. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density-lipoprotein-cholesterol: analysis of five phase 3 clinical trials. Arthritis Rheum 2008, S785.
30. McInnes I.B., Kim H.Y., Lee S.H., Mandel D., Song Y.W., Connell C.A., et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2013, 0:1-8.
31. Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009, 38:23-27.
32. Charles-Schoeman C., Khanna D., Furst D.E., McMahon M., Reddy S.T., Fogelman A.M., et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007, 34:1459-1464.
33. Onat A., Can G., Kaya H., Hergenç G. Atherogenic index of plasma (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol 2010, 4:89-98.
34. Dobiásová M., Frohlich J., Sedová M., Cheung M.C., Brown B.G. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res 2011, 52:566-571.
35. McInnes I.B., Lee Iain B., Wu Janet S., Giles Wen, Bathon Jon T., Salmon Joan M., et al. Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study. Arthritis Rheum 2010, 1441.
36. Kremer J.M., Van Vollenhoven R.F., Ridley D.J. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow up duration of 1.5 years. Arthritis Rheum 2008, S783-S784.
37. Feuer E.J., Lee M., Mariotto A.B., Cronin K.A., Scoppa S., Penson D.F., et al. The cancer survival query system: making survival estimates from the surveillance, epidemiology, and end results program more timely and relevant for recently diagnosed patients. Cancer 2012, 118(22):5652-5662.
38. Anderson L.A., Pfeiffer R.M., Landgren O., Gadalla S., Berndt S.I., Engels E.A. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009, 100:822-828.
39. Beauparlant P., Papp K., Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999, 29:148-158.
40. Smolen J.S., Beaulieu A., Dikranian A., et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008, 54(suppl 9):784. [abstract 1669].
41. Van Vollenhoven R.F., Keystone E.C., Furie R., Blesch A., Wang C., Curtis J.R. Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials. Arthritis Rheum 2009, 60(suppl 10):1613. [abstract].
42. Makol A., Wright K., Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 2011, 71:1973-1987.
43. Pham T., Claudepierre P., Constantin A., de Bandt M., Fautrel B., Gossec L., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77:S3-100.